Other BCR-ABL inhibitors, such as bosutinib, dasatinib, nilotinib, and ponatinib, have also been shown to be effective in CML and acute lymphoblastic leukemia [91]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.